Somewhat Favorable Press Coverage Somewhat Unlikely to Impact NxStage Medical (NXTM) Share Price
Media coverage about NxStage Medical (NASDAQ:NXTM) has been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern scores the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. NxStage Medical earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the medical device company an impact score of 45.3479473834843 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- NxStage Medical Prepares for Fresenius Merger (fool.com)
- $102.29 Million in Sales Expected for NxStage Medical, Inc. (NXTM) This Quarter (americanbankingnews.com)
- NxStage Medical, Inc. (NXTM) Expected to Post Quarterly Sales of $102.29 Million (americanbankingnews.com)
- Winifred L. Swan Sells 3,500 Shares of NxStage Medical, Inc. (NXTM) Stock (americanbankingnews.com)
Shares of NxStage Medical (NXTM) traded up $0.68 on Wednesday, reaching $26.58. The company had a trading volume of 312,100 shares, compared to its average volume of 818,331. NxStage Medical has a 1 year low of $20.45 and a 1 year high of $30.80.
A number of research firms have recently issued reports on NXTM. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research note on Thursday, August 10th. Stephens lowered NxStage Medical from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $33.00 to $30.00 in a research note on Wednesday, August 9th. Canaccord Genuity reiterated a “hold” rating and issued a $30.00 target price on shares of NxStage Medical in a research note on Tuesday, October 17th. Northland Securities restated a “hold” rating and set a $30.00 price objective on shares of NxStage Medical in a research note on Monday, August 7th. Finally, Craig Hallum lowered NxStage Medical from a “buy” rating to a “hold” rating in a research note on Monday, August 7th. Two equities research analysts have rated the stock with a sell rating and eight have issued a hold rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $30.25.
COPYRIGHT VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact NxStage Medical (NXTM) Share Price” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/11/22/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-nxstage-medical-nxtm-share-price.html.
In other NxStage Medical news, SVP Winifred L. Swan sold 3,500 shares of the company’s stock in a transaction on Friday, October 20th. The stock was sold at an average price of $27.50, for a total transaction of $96,250.00. Following the transaction, the senior vice president now owns 15,270 shares of the company’s stock, valued at approximately $419,925. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Matthew W. Towse sold 4,300 shares of the company’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $27.27, for a total value of $117,261.00. Following the transaction, the senior vice president now directly owns 28,721 shares in the company, valued at approximately $783,221.67. The disclosure for this sale can be found here. Insiders have sold 13,300 shares of company stock worth $359,076 over the last ninety days. Company insiders own 4.70% of the company’s stock.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.